You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥-B(06855.HK)IAP拮抗劑臨床研究顯示呈現功能性治癒慢性乙肝潛力
阿思達克 11-07 09:17
亞盛醫藥-B(06855.HK)公布,在第73屆美國肝病研究學會年會(AASLD 2022)上以口頭報告形式公布其在研凋亡蛋白抑制因子(IAP)拮抗劑APG-1387針對中國慢性乙型肝炎(CHB)患者的I期臨床試驗的研究結果。 該項臨床數據顯示,APG-1387在12 mg和30 mg劑量下呈現明顯的抗乙型肝炎病毒(HBV)活性,且與核(甘)(酸)類似物(NA)序貫治療具有積極的協同作用。而APG-1387治療慢乙肝患者整體是安全且可耐受,呈現功能性治癒慢性乙肝潛力。 此外,公司目前一項APG-1387聯合恩替卡韋的II期臨床研究(NCT04568265)正在進行。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account